Actualités ac99/a1811
Neoadjuvant SHR-A1811 Demonstrates Efficacy, Safety in HER2+ Breast Cancer
Tue, 10 Dec 2024 16:00:00 GMT
SHR-A1811 showed promising antitumor activity and acceptable tolerability in patients with HER2-positive breast cancer, according to results of the phase 2 FASCINATE-N trial. The third-generation ...